 |
54 Diseases |  |
3 Trials |
|
3 Trials |  |
642 News |  |
| «12345678» |
- dactolisib (RTB101) / Adicet Bio
Trial termination, Metastases: BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Feb 29, 2016
P1/2, N=10, Terminated, Sponsor: Memorial Sloan Kettering Cancer Center
Completed --> Terminated; Given the number of toxicities seen and the difficulty with patient retention in the dose escalation portion, the sponsor decided to close the trial.
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (clinicaltrials.gov) - Feb 24, 2016
P2b, N=58, Enrolling by invitation, Sponsor: Medical Research Council
Completed --> Terminated; Given the number of toxicities seen and the difficulty with patient retention in the dose escalation portion, the sponsor decided to close the trial. Active, not recruiting --> Enrolling by invitation
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Trial primary completion date: Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (clinicaltrials.gov) - Nov 30, 2015
P2b, N=58, Active, not recruiting, Sponsor: Medical Research Council
Active, not recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Nov 2015
- | dactolisib (RTB101) / Adicet Bio
Trial completion: BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. (clinicaltrials.gov) - Oct 7, 2015
P2, N=31, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Nov 2015 Active, not recruiting --> Completed
- dactolisib (RTB101) / Adicet Bio
Enrollment change, Trial primary completion date: A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Oct 5, 2015
P1/2, N=6, Terminated, Sponsor: Charles Ryan
Active, not recruiting --> Completed N=74 --> 6 | Trial primary completion date: Jan 2015 --> Jan 2014
- | buparlisib (AN2025) / Adlai Nortye, dactolisib (RTB101) / Adicet Bio
Trial completion, Trial primary completion date: Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients (clinicaltrials.gov) - Sep 14, 2015
P1, N=43, Completed, Sponsor: Novartis Pharmaceuticals
N=74 --> 6 | Trial primary completion date: Jan 2015 --> Jan 2014 Active, not recruiting --> Completed | Trial primary completion date: Oct 2014 --> Jul 2015
- || Keytruda (pembrolizumab) / Merck (MSD)
Enrollment status: Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (clinicaltrials.gov) - Aug 25, 2015
P2b, N=58, Recruiting, Sponsor: Medical Research Council
Active, not recruiting --> Completed | Trial primary completion date: Oct 2014 --> Jul 2015 Enrolling by invitation --> Recruiting
- || Keytruda (pembrolizumab) / Merck (MSD)
Enrollment status: Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (clinicaltrials.gov) - Jun 18, 2015
P2b, N=58, Enrolling by invitation, Sponsor: Medical Research Council
Enrolling by invitation --> Recruiting Recruiting --> Enrolling by invitation
- dactolisib (RTB101) / Adicet Bio
Trial primary completion date: BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. (clinicaltrials.gov) - Jun 11, 2015
P2, N=31, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Enrolling by invitation Trial primary completion date: Jan 2015 --> Jun 2015
- |||||| Keytruda (pembrolizumab) / Merck (MSD)
New P2b trial: Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (clinicaltrials.gov) - Apr 30, 2015
P2b, N=58, Recruiting, Sponsor: Medical Research Council
- | dactolisib (RTB101) / Adicet Bio
Trial completion, Combination therapy, Metastases: Dose Finding Study of RAD001 (Everolimus, Afinitor (clinicaltrials.gov) - Mar 2, 2015
P1, N=46, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jan 2015 --> Jun 2015 Active, not recruiting --> Completed
- ||| buparlisib (AN2025) / Adlai Nortye, dactolisib (RTB101) / Adicet Bio
Trial completion: A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab (clinicaltrials.gov) - Jan 17, 2015
P1, N=110, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| dactolisib (RTB101) / Adicet Bio
Trial completion, Enrollment change: Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Nov 24, 2014
P2, N=62, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed | N=140 --> 62
- dactolisib (RTB101) / Adicet Bio
Trial primary completion date, Combination therapy, Metastases: Dose Finding Study of RAD001 (Everolimus, Afinitor (clinicaltrials.gov) - Nov 19, 2014
P1, N=46, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=140 --> 62 Trial primary completion date: Aug 2014 --> Apr 2015
- dactolisib (RTB101) / Adicet Bio
Trial primary completion date: BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. (clinicaltrials.gov) - Oct 31, 2014
P2, N=31, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2014 --> Apr 2015 Trial primary completion date: Jun 2014 --> Jan 2015
- || buparlisib (AN2025) / Adlai Nortye, dactolisib (RTB101) / Adicet Bio
Trial primary completion date: A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab (clinicaltrials.gov) - Oct 4, 2014
P1, N=110, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2014 --> Jan 2015 Trial primary completion date: May 2014 --> Dec 2014
- buparlisib (AN2025) / Adlai Nortye, dactolisib (RTB101) / Adicet Bio
Enrollment closed, Enrollment change, Trial primary completion date: Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients (clinicaltrials.gov) - Sep 15, 2014
P1, N=43, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: May 2014 --> Dec 2014 Recruiting --> Active, not recruiting | N=122 --> 43 | Trial primary completion date: Oct 2015 --> Oct 2014
- | dactolisib (RTB101) / Adicet Bio
Trial completion, Trial primary completion date, Metastases: Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jul 23, 2014
P2, N=18, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=122 --> 43 | Trial primary completion date: Oct 2015 --> Oct 2014 Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> May 2014
- dactolisib (RTB101) / Adicet Bio
Trial primary completion date, Monotherapy, Metastases: Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy (clinicaltrials.gov) - May 12, 2014
P2, N=22, Terminated, Sponsor: Cliniques universitaires Saint-Luc- Universit
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> May 2014 Trial primary completion date: Jan 2015 --> Jan 2014
- dactolisib (RTB101) / Adicet Bio
Trial termination, Monotherapy, Metastases: Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy (clinicaltrials.gov) - May 12, 2014
P2, N=22, Terminated, Sponsor: Cliniques universitaires Saint-Luc- Universit
Trial primary completion date: Jan 2015 --> Jan 2014 Active, not recruiting --> Terminated; Novartis decided to stop the marketing of BEZ235
- dactolisib (RTB101) / Adicet Bio
Trial completion date, Monotherapy, Metastases: Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy (clinicaltrials.gov) - May 12, 2014
P2, N=22, Terminated, Sponsor: Cliniques universitaires Saint-Luc- Universit
Active, not recruiting --> Terminated; Novartis decided to stop the marketing of BEZ235 Trial completion date: Jan 2016 --> Jan 2014
- dactolisib (RTB101) / Adicet Bio
Enrollment change, Monotherapy, Metastases: Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy (clinicaltrials.gov) - May 12, 2014
P2, N=22, Terminated, Sponsor: Cliniques universitaires Saint-Luc- Universit
Trial completion date: Jan 2016 --> Jan 2014 N=38 --> 22
- || dactolisib (RTB101) / Adicet Bio
Trial primary completion date: Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Apr 20, 2014
P2, N=140, Recruiting, Sponsor: Novartis Pharmaceuticals
N=38 --> 22 Trial primary completion date: Sep 2014 --> Jul 2014
- || dactolisib (RTB101) / Adicet Bio
Trial completion date: Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Apr 20, 2014
P2, N=140, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2014 --> Jul 2014 Trial completion date: Sep 2014 --> Jul 2014
- dactolisib (RTB101) / Adicet Bio
Trial completion, Metastases: BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Apr 8, 2014
P1/2, N=10, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial completion date: Sep 2014 --> Jul 2014 Active, not recruiting --> Completed
- | dactolisib (RTB101) / Adicet Bio
Enrollment change: BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. (clinicaltrials.gov) - Apr 6, 2014
P2, N=31, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=130 --> 31
- | dactolisib (RTB101) / Adicet Bio
Enrollment closed: BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. (clinicaltrials.gov) - Apr 6, 2014
P2, N=31, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=130 --> 31 Recruiting --> Active, not recruiting
- | dactolisib (RTB101) / Adicet Bio
Trial completion: Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors (clinicaltrials.gov) - Mar 25, 2014
P1, N=33, Completed, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- buparlisib (AN2025) / Adlai Nortye, dactolisib (RTB101) / Adicet Bio
Trial completion: PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer (clinicaltrials.gov) - Feb 13, 2014
P1, N=72, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | dactolisib (RTB101) / Adicet Bio
Enrollment change, Metastases: Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Feb 4, 2014
P2, N=18, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=230 --> 18
- | dactolisib (RTB101) / Adicet Bio
Enrollment closed, Metastases: Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Feb 4, 2014
P2, N=18, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=230 --> 18 Recruiting --> Active, not recruiting
- | dactolisib (RTB101) / Adicet Bio
Trial termination: A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Dec 18, 2013
P1/2, N=74, Terminated, Sponsor: Charles Ryan
Recruiting --> Active, not recruiting Recruiting --> Terminated; Dose limiting toxicities on lowest dose level
- dactolisib (RTB101) / Adicet Bio
Enrollment change, Combination therapy, Metastases: Dose Finding Study of RAD001 (Everolimus, Afinitor (clinicaltrials.gov) - Dec 5, 2013
P1, N=46, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Terminated; Dose limiting toxicities on lowest dose level N=73 --> 46
- dactolisib (RTB101) / Adicet Bio
Enrollment closed, Combination therapy, Metastases: Dose Finding Study of RAD001 (Everolimus, Afinitor (clinicaltrials.gov) - Dec 3, 2013
P1, N=46, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=73 --> 46 Suspended --> Active, not recruiting
- | dactolisib (RTB101) / Adicet Bio
Enrollment closed, Monotherapy, Metastases: Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy (clinicaltrials.gov) - Nov 21, 2013
P2, N=38, Active, not recruiting, Sponsor: Cliniques universitaires Saint-Luc- Universit
Suspended --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| dactolisib (RTB101) / Adicet Bio
Enrollment change, Metastases: A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer (clinicaltrials.gov) - Nov 18, 2013
P1/2, N=183, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=244 --> 183
- dactolisib (RTB101) / Adicet Bio
Enrollment closed: A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia (clinicaltrials.gov) - Nov 11, 2013
P1, N=23, Active, not recruiting, Sponsor: Johann Wolfgang Goethe University Hospitals
N=244 --> 183 Recruiting --> Active, not recruiting
- Mektovi (binimetinib) / Pfizer
Enrollment change: Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients (clinicaltrials.gov) - Oct 24, 2013
P1, N=29, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=80 --> 29
- | Mektovi (binimetinib) / Pfizer
Trial completion: Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients (clinicaltrials.gov) - Oct 24, 2013
P1, N=29, Completed, Sponsor: Novartis Pharmaceuticals
N=80 --> 29 Active, not recruiting --> Completed
- dactolisib (RTB101) / Adicet Bio
Trial withdrawal, Monotherapy: A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa (clinicaltrials.gov) - Jul 31, 2013
P2, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Withdrawn
- dactolisib (RTB101) / Adicet Bio
Enrollment change, Monotherapy: A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa (clinicaltrials.gov) - Jul 31, 2013
P2, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Recruiting --> Withdrawn N=33 --> 0
- | dactolisib (RTB101) / Adicet Bio
New P2 trial, Monotherapy, Metastases: Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy (clinicaltrials.gov) - May 15, 2013
P2, N=38, Active, not recruiting, Sponsor: Cliniques universitaires Saint-Luc- Universit
- || buparlisib (AN2025) / Adlai Nortye, dactolisib (RTB101) / Adicet Bio
Enrollment change: A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab (clinicaltrials.gov) - May 14, 2013
P1, N=110, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=33 --> 0 N=72 --> 110
- dactolisib (RTB101) / Adicet Bio
Enrollment change, Metastases: BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - May 8, 2013
P1/2, N=10, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=72 --> 110 N=55 --> 10
- || buparlisib (AN2025) / Adlai Nortye, dactolisib (RTB101) / Adicet Bio
Enrollment closed: A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab (clinicaltrials.gov) - Apr 15, 2013
P1, N=110, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=55 --> 10 Recruiting --> Active, not recruiting
- |||| dactolisib (RTB101) / Adicet Bio
Trial completion, Metastases: A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer (clinicaltrials.gov) - Mar 3, 2013
P1/2, N=183, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| dactolisib (RTB101) / Adicet Bio
Enrollment open: Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Jan 7, 2013
P2, N=140, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- dactolisib (RTB101) / Adicet Bio
New P1 trial: A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia (clinicaltrials.gov) - Dec 20, 2012
P1, N=23, Active, not recruiting, Sponsor: Johann Wolfgang Goethe University Hospitals
- dactolisib (RTB101) / Adicet Bio
Enrollment change: A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab (clinicaltrials.gov) - Nov 29, 2012
P2, N=5, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=140 --> 5
- dactolisib (RTB101) / Adicet Bio
Trial completion: A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab (clinicaltrials.gov) - Nov 29, 2012
P2, N=5, Completed, Sponsor: Novartis Pharmaceuticals
N=140 --> 5 Recruiting --> Completed